At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 109 enrolled
Drug / intervention
Isotretinoindrug
Likely dose
Isotretinoin 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Determining the Effect of Low-dose Isotretinoin on Proliferative Vitreoretinopathy
In Brief
A Phase 4 clinical trial evaluating Isotretinoin for Proliferative Vitreoretinopathy. Completed, enrolled 109 participants across 1 site.
Detailed Summary
Proliferative vitreoretinopathy (PVR), or secondary scarring on and around the retina, is an important cause of retinal re-detachment. The purpose of this study is to evaluate the effect of oral isotretinoin, which inhibits the growth of cells responsible for proliferative vitreoretinopathy (PVR), on recurrent retinal detachment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProliferative Vitreoretinopathy
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2011
First PostedOct 2011
Primary CompletionAug 2013
Study CompletionAug 2015
TodayJul 2026
First PostedOct 3, 2011
Enrollment StartSep 1, 2011
Primary CompletionAug 1, 2013
Study CompletionAug 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 14.7 years ago
Interventions
Isotretinoindrug
Isotretinoin 20mg daily for 12 weeks